Mumbai: Patient Centricity and Integrated Quality Management is the theme for this year’s India Pharmaceutical Forum, organized by the Indian Pharmaceutical Alliance (IPA) in Mumbai. Now in its 5th edition, the event brought together manufacturers, regulators, academia and other relevant stakeholders together facilitate discussions resulting in meaningful and actionable outcomes. Dr VG Somani, Drugs Controller General India delivered the Keynote Address and released the IPA guidelines on Market Complaints.

 “Indian Pharmaceutical Forum (IPF) is a pioneering initiative of IPA that lays a strong foundation for quality culture and capability building. Quality is fundamental to our industry and would help to take India to next level. This Forum is a unique platform which brings together all stakeholders comprising of Indian and global regulators, government policymakers, industry, academia to move forward the quality agenda. This year’s theme Patient Centricity and Integrated Quality Management will be pivotal for our journey on quality,” said Mr. Sudarshan Jain, Secretary-General, Indian Pharmaceutical Alliance

The 2020 Forum focused on patient-centric approach to the manufacturing of quality medicines. With ten sessions spread over two days, the conference focused on some of the pressing issues in pharmaceutical industry such as Quality, Capability Building, Affordability and Patient-Centric Approach among other topics. With international and Indian stakeholders coming together to discuss pertinent issues related to quality management systems and thereof, the Forum brought together the relevant stakeholders in the Pharmaceutical industry to map a way forward for the Indian pharmaceutical industry.

“Indian pharma has made considerable progress in our quality journey. Forums such as the IPF play a significant role in achieving the vision of the industry – to be the global benchmark in quality. Several eminent speakers participated in this edition of the IPF and made it an enriching experience,” said Mr. Satish Reddy, President, Indian Pharmaceutical Alliance and Chairman, Dr. Reddy’s Laboratories Ltd.

He added, “The US has been under increasing pressure for exports; however, it is still the largest market for us. There has also been an increasing focus on China to tap into the emerging market of generics. With India being a major player in the generics market, we need set the global benchmark in quality.  We need to create an industry culture where people do the right thing and speak up if anything wrong happens.”

The CEO Panel on Patient Centricity and Integrated Quality Management by the CEO’s of Lupin, Dr. Reddy’s Laboratories, Sun Pharmaceuticals, Cadila Healthcare, and Cipla reflected thoughts on the Indian pharmaceutical industry current standing and the path ahead.